Hepatitis C News and Research

Latest Hepatitis C News and Research

UCL-led team develops new technique to find resistant TB faster

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks.

From Oxford Gene Technology 13 May 2015

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy, according to a report in the May issue of Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

13 May 2015

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Progress in child survival worldwide is one of the greatest success stories of international development. Since 1990, child deaths have almost halved – falling from an estimated 90 deaths per 1000 live births to 46 deaths per 1000 live births in 2013...

13 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015.

13 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV...

7 May 2015

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association.

7 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Matteo Iannacone of the San Raffaele Scientific Institute in Milan where intravital microscopy is being applied to the study of host-viruses and associated immune responses.

7 May 2015

New study finds high levels of HCV infection among HIV-infected people across Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

6 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

5 May 2015

TDF switch effective in Asian chronic HBV patients

Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients.

29 Apr 2015

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

In patients with chronic hepatitis B virus infection, treatment with tenofovir disoproxil fumarate does not significantly increase the risk of developing renal dysfunction compared with entecavir treatment, a US team reports.

29 Apr 2015

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Tenofovir disoproxil fumarate alone elicits a response comparable to that of TDF plus entecavir in heavily pretreated patients with chronic hepatitis B virus infection resistant to adefovir dipivoxil, research suggests.

29 Apr 2015

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Our analysis shows that these drugs would not save overall healthcare money, but would add to the budget. When something is cost effective, it does not necessarily mean it is going to save money. It essentially implies that we're willing to spend additional money to gain additional benefits...

28 Apr 2015

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.

27 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).

27 Apr 2015

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

25 Apr 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

UCL-led team develops new technique to find resistant TB faster

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Galmed reports net loss of $2.5 million for first quarter 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

New study finds high levels of HCV infection among HIV-infected people across Africa

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

TDF switch effective in Asian chronic HBV patients

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Hepatitis C News and Research

Latest Hepatitis C News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in